CVKD
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ: CVKD · HEALTHCARE · BIOTECHNOLOGY
$6.67
+19.32% today
Updated 2026-04-30
Market cap
$13.79M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.64
Dividend yield
—
52W range
$4 – $17
Volume
0.1M
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $1266.00 | $1980.00 | $1880.00 | — |
| Gross profit | $-1266.00 | $-1980.00 | $-1880.00 | — |
| Gross margin | — | — | — | — |
| R&D | $392859.00 | $4.08M | $4.21M | $4.10M |
| SG&A | — | $3.55M | $6.75M | $9.35M |
| Operating income | $-2.70M | $-7.63M | $-10.96M | $-13.46M |
| Operating margin | — | — | — | — |
| EBITDA | $-6.61M | $-8.34M | $-10.65M | $-13.46M |
| EBITDA margin | — | — | — | — |
| EBIT | $-6.61M | $-8.34M | $-10.65M | $-13.47M |
| Interest expense | $107105.00 | $17101.00 | $0.00 | — |
| Income tax | $4.00 | $-165915.00 | — | — |
| Effective tax rate | -0.0% | 1.9% | 0.0% | 0.0% |
| Net income | $-6.71M | $-8.36M | $-10.65M | $-13.24M |
| Net income growth (YoY) | — | -24.5% | -27.5% | -24.3% |
| Profit margin | — | — | — | — |